Cancer Risk After Medical Treatment, edited by Michel P. Coleman, 184 pp, $45, ISBN 0-19-26181-8, New York, NY, Oxford University Press, 1991.
One in 1000 adults turning 20 years old is a cancer survivor, and every practicing physician will soon have survivors as patients. The iatrogenic diseases of successful cancer therapy are crippling our patients.
Pediatric oncology has transformed pediatric malignancy from a hopeless to a hopeful outlook. Now pediatric oncologists ask, how can we cure without such serious sequelae? Monitoring late effects is now incorporated into the cooperative group protocols, and some institutions have established clinics to assist long-term survivors with complications. We need to optimize these lives so hard fought for.
This monograph is part of the Current Clinical Oncology series. It catalogs problems by organ system, and thus duplication is minimized. It also makes it easy for the reader to review a specific problem of interest, eg,